Agios Pharmaceuticals Inc SEC Filings

Agios Pharmaceuticals (AGIO) reported an insider transaction by its Chief Medical Officer, Sarah Gheuens. On 10/30/2025, she exercised 200 stock options at $25.01 per share and sold 200 shares at $43.81 pursuant to a Rule 10b5-1 trading plan. Following these trades, she held 61,727 shares of common stock directly.

The derivative table shows 28,584 stock options beneficially owned after the transaction, with an exercise price of $25.01 and an expiration date of 03/01/2033. The option was originally granted on 03/01/2023 for 44,000 shares, vesting 25% on 03/01/2024 with the remainder vesting in 36 equal monthly installments thereafter.

Agios Pharmaceuticals (AGIO) reported Q3 2025 results. Product revenue reached $12.9 million, up from $9.0 million a year ago, driven by PYRUKYND sales. Operating expenses included $86.8 million in research and development and $41.3 million in selling, general and administrative costs, leading to a net loss of $103.4 million for the quarter.

The company ended the period with $1.3 billion in cash, cash equivalents and marketable securities as of September 30, 2025. PYRUKYND advanced internationally: the Saudi Food and Drug Authority approved the thalassemia indication, and Europe’s CHMP issued a positive opinion. In the U.S., the FDA accepted the sNDA for thalassemia and set a PDUFA goal date of December 7, 2025 following a REMS submission.

For the first nine months of 2025, product revenue was $34.1 million versus $25.8 million in 2024, reflecting continued commercial execution while development spending supports the pipeline.

Agios Pharmaceuticals (AGIO) furnished an 8-K announcing it issued a press release with results for the quarter ended September 30, 2025 and other business highlights. The press release is provided as Exhibit 99.1. The company states this information, including Exhibit 99.1, is furnished and not deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced.

Agios Pharmaceuticals (AGIO) reported an insider transaction by its Chief Medical Officer on 10/27/2025. The officer exercised 3,302 stock options at $25.01 per share and sold 3,302 common shares at a $43.92 weighted average price pursuant to a Rule 10b5-1 trading plan.

Following these transactions, the officer directly beneficially owned 61,727 common shares. The filing also lists 28,784 stock options remaining beneficially owned. The sale price ranged from $43.77 to $44.13, and the reporting person undertakes to provide the detailed breakdown upon request. Footnotes note that ownership includes 456 shares acquired through the employee stock purchase plan and that the exercised option was part of a grant originally awarded on March 1, 2023.

Insider transactions by Director David Scadden show option exercise and a share sale under a 10b5-1 plan. On 10/08/2025 Mr. Scadden exercised 200 stock options with an $18.09 exercise price, creating 200 new shares.

He simultaneously sold 200 shares at $41, leaving him with 17,603 shares of common stock directly and 27,107 shares underlying options and other derivative holdings in total. The exercise option was originally granted on 06/21/2022 and vests 100% one year from the grant date. The transactions were made pursuant to a Rule 10b5-1 trading plan.

Insider sale notice under Rule 144: This Form 144 records a proposed sale of 200 common shares by an insider through Morgan Stanley Smith Barney LLC on 10/08/2025 with an stated aggregate market value of $8,200.00. The shares were acquired and paid for by stock option exercise on 10/08/2025 with cash payment.

The filer also reported three prior sales by the same person in the past three months: 200 shares on 09/30/2025 for $8,000.00, 200 shares on 08/27/2025 for $8,000.00, and 1,400 shares on 07/10/2025 for $56,000.00, totaling 1,800 shares and $72,000.00 in gross proceeds over three months. The notice includes the standard insider representation about absence of undisclosed material adverse information.

David Scadden, a director of Agios Pharmaceuticals (AGIO), reported trading activity executed on 09/30/2025 under a Rule 10b5-1 trading plan. The filing shows a purchase of 200 common shares at $18.09 and a sale of 200 common shares at $40.00 on the same date. After those transactions Mr. Scadden reported beneficial ownership of 17,603 shares of common stock and, including derivative holdings, 27,307 shares underlying options.

The Form 4 also reports an option grant with an exercise price of $18.09 and an expiration date of 06/21/2032. The filer notes the option grant was originally made on 06/21/2022 and that the underlying shares vest 100% one year from the grant date. The filing is signed by an attorney-in-fact on 10/02/2025.

Cecilia Jones, Chief Financial Officer of Agios Pharmaceuticals (AGIO) reported the vesting of 7,472 restricted stock units and a contemporaneous automatic sale of 3,651 shares to satisfy tax withholding obligations. The sale price reported was $36.77 per share, and following these transactions she beneficially owned 33,870 shares. The RSUs were originally granted on September 26, 2022 and vest in three equal annual installments beginning September 26, 2023. The tax-withholding sale was executed under pre-existing durable automatic sale instructions consistent with a Rule 10b5-1 plan.

Form 144 filed for Agios Pharmaceuticals (AGIO) reporting proposed sale of common shares by an insider. The notice identifies David T. Scadden as the person for whose account the securities will be sold. The filing shows 200 shares intended for sale through Morgan Stanley Smith Barney LLC on 09/30/2025 with an aggregate market value of $8,000. The shares were acquired by a stock option exercise on 09/30/2025 and paid for in cash. The filing also discloses two prior sales by the reporting person within the past three months: 200 shares on 08/27/2025 for $8,000 and 1,400 shares on 07/10/2025 for $56,000. The notice includes the required representation that the seller does not possess undisclosed material adverse information.